These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 29121019)
1. Duchenne drug clings on for FDA nod. Nat Biotechnol; 2017 Nov; 35(11):999. PubMed ID: 29121019 [No Abstract] [Full Text] [Related]
2. FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga. Aartsma-Rus A; Krieg AM Nucleic Acid Ther; 2017 Feb; 27(1):1-3. PubMed ID: 27929755 [No Abstract] [Full Text] [Related]
3. Railroading at the FDA. Nat Biotechnol; 2016 Nov; 34(11):1078. PubMed ID: 27824847 [No Abstract] [Full Text] [Related]
4. Eteplirsen Approved for Duchenne Muscular Dystrophy: The FDA Faces a Difficult Choice. Stein CA Mol Ther; 2016 Nov; 24(11):1884-1885. PubMed ID: 27916994 [No Abstract] [Full Text] [Related]
5. EMA reconsiders 'read-through' drug against Duchenne muscular dystrophy following appeal. Mullard A Nat Biotechnol; 2014 Aug; 32(8):706. PubMed ID: 25101726 [No Abstract] [Full Text] [Related]
6. European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene. Haas M; Vlcek V; Balabanov P; Salmonson T; Bakchine S; Markey G; Weise M; Schlosser-Weber G; Brohmann H; Yerro CP; Mendizabal MR; Stoyanova-Beninska V; Hillege HL Neuromuscul Disord; 2015 Jan; 25(1):5-13. PubMed ID: 25497400 [No Abstract] [Full Text] [Related]
7. Duchenne muscular dystrophy drugs face tough path to approval. Hodgkinson L; Sorbera L; Graul AI Drugs Today (Barc); 2016 Mar; 52(3):199-202. PubMed ID: 27186594 [TBL] [Abstract][Full Text] [Related]
8. Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy. Kesselheim AS; Avorn J JAMA; 2016 Dec; 316(22):2357-2358. PubMed ID: 27775756 [No Abstract] [Full Text] [Related]
9. Railroading at the FDA. Nat Med; 2016 Nov; 22(11):1193. PubMed ID: 27824816 [No Abstract] [Full Text] [Related]
10. Muscular dystrophy drug looks set for commercial success despite clinical doubts. Dyer O BMJ; 2016 Oct; 355():i5346. PubMed ID: 27698204 [No Abstract] [Full Text] [Related]
11. Reading through premature stop codons with PTC1 24. Project Catalyst to find more Duchenne drugs. Interview by Guenter Scheuerbrandt. Welch E; Goetz D; Almstead N Acta Myol; 2008 Oct; 27():63-8. PubMed ID: 19364064 [No Abstract] [Full Text] [Related]
15. Ataluren: first global approval. Ryan NJ Drugs; 2014 Sep; 74(14):1709-14. PubMed ID: 25193627 [TBL] [Abstract][Full Text] [Related]
16. A Sequel to the Eteplirsen Saga: Eteplirsen Is Approved in the United States but Was Not Approved in Europe. Aartsma-Rus A; Goemans N Nucleic Acid Ther; 2019 Feb; 29(1):13-15. PubMed ID: 30526286 [TBL] [Abstract][Full Text] [Related]
17. Patient need versus evidence: a balancing act. The Lancet Lancet; 2016 Oct; 388(10052):1350. PubMed ID: 27707475 [No Abstract] [Full Text] [Related]
19. [Patients organizations and new drug approval in the US. Eteplirsen and Duchenne muscular dystrophy case]. Dal-Ré R; Lopez de Munain A; Ayuso C Rev Neurol; 2017 Oct; 65(8):373-380. PubMed ID: 28990648 [TBL] [Abstract][Full Text] [Related]